CLINICAL TRIALS PROFILE FOR ARGININE HYDROCHLORIDE
✉ Email this page to a colleague
505(b)(2) Clinical Trials for arginine hydrochloride
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| OTC | NCT02675660 ↗ | Single and Multiple Doses of an Oral Formulation of L-Homoarginine in Healthy Human Subjects | Completed | Universitätsklinikum Hamburg-Eppendorf | Phase 1 | 2014-04-01 | This study represents an initial clinical evaluation of an oral formulation of L-homoarginine. L-homoarginine and L-arginine are amino acids found in food proteins and are both substrates for nitric oxide synthase (NOS). L-arginine is available as over the counter nutraceutical. This study will provide information on the dosing of L-homoarginine in order to reach high physiological plasma concentrations in humans. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for arginine hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000623 ↗ | Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN) | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 2000-07-01 | The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used. | |
| NCT00000623 ↗ | Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN) | Completed | Thalassemia Clinical Research Network | 2000-07-01 | The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used. | |
| NCT00000623 ↗ | Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN) | Completed | HealthCore-NERI | 2000-07-01 | The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used. | |
| NCT00000623 ↗ | Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN) | Completed | New England Research Institutes | 2000-07-01 | The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used. | |
| NCT00001436 ↗ | A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With Osteosarcoma | Completed | National Cancer Institute (NCI) | Phase 1 | 1995-05-01 | The suppression of IGF-I and growth hormone may significantly alter the pathobiology of osteosarcoma. SMS 201-955 pa LAR is a long acting analog of Somatostatin which inhibits the pituitary release of growth hormone, reducing levels of circulating IGF-I . Additional data on tamoxifen usage has also demonstrated a reduction in circulating IGF-I levels. The degree of suppression of IGF-I and growth hormone will be determined at two dose levels of SMS 291-955 pa LAR. Tamoxifen will be added to two of the cohorts to determine if the additive effects of tamoxifen and SMS 201-955 pa LAR will lead to additional reduction of circulating IGF-I and growth hormone levels. Arginine-stimulated GH tests to assess levels of growth hormone in the blood will be administered pre-treatment evaluation up to three times, one time on weeks 2, 8, 16, 28, 40, 52, and one month post last dose of SMS 201-955 pa LAR. The four cohorts for this study will receive 60 or 90 mg SMS 201-955 pa LAR injectable every four weeks for up to 52 weeks. Two of the cohorts will receive 10 mg Tamoxifen on a daily basis. |
| NCT00001752 ↗ | Vascular and Metabolic Effects of Hormone Therapy Combined With L-Arginine in Postmenopausal Women | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 | 1998-09-01 | Estrogen therapy has been associated with reduced risk of coronary heart disease events in observational studies of postmenopausal women. Although favorable effects of estrogen on lipoprotein cholesterol levels probably account for much of this benefit, direct vascular effects (vasomotor, hemostatic, anti-inflammatory) regulated by nitric oxide (NO) may also be of importance. We have recently shown that vasodilator effects of estrogen in the coronary circulation are due to enhanced bioactivity of NO released from the endothelium. Estrogen has been shown to stimulate synthesis and activity of the enzyme NO synthase with enhanced NO synthesis in endothelial cells in culture. Because L-arginine is the natural substrate for the enzyme NO synthase, we propose that the combination of L-arginine and estrogen might have additive vasomotor, hemostatic and anti-inflammatory effects in hypercholesterolemic postmenopausal women. |
| NCT00004360 ↗ | Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus | Completed | Northwestern University | 1995-09-01 | OBJECTIVES: I. Determine the relationship between genotype variations and clinical phenotype in patients with congenital nephrogenic diabetes insipidus. | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for arginine hydrochloride
Condition Name
Clinical Trial Locations for arginine hydrochloride
Trials by Country
Clinical Trial Progress for arginine hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for arginine hydrochloride
Sponsor Name
